New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds
FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.
Reference News
New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds
FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.